Best Practices for genomic biomarkers

The European Medicines Agency (EMA) has released a draft concept paper  outlining the key elements that will be developed in a guideline on good genomics biomarker practices. With this guidance the EMA aims to enhance transparency, consistency, reproducibility and cross-validation between genomic-driven studies. This is expected to promote and facilitate the use of genomic data for the development of so-called personalised medicines, the safety monitoring of medicines and the early diagnosis of disease. For more information, please visit the official website of EMA.